The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJOncoAlert Journal Club | AMPLIFY-201: a lymph node-targeted, mKRAS-specific vaccine in pancreatic & colorectal cancer
In this week’s episode of the VJOncoAlert Journal Club, Zev Wainberg, MD, University of California Los Angeles, Los Angeles, CA, discusses results from the Phase I AMPLIFY-201 trial (NCT04853017) of the lymph node–targeted amphiphile vaccine ELI-002 2P in patients with minimal residual pancreatic or colorectal cancer harboring mKRAS mutations. Vaccination induced robust CD4+ and CD8+ T-cell responses, with evidence of antigen spreading to additional tumor-specific targets. Stronger immune responses correlated with improved relapse-free and overall survival. The findings support the potential of mKRAS-targeted vaccines to generate durable immunity and improve outcomes in gastrointestinal cancers.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
